Acorda Therapeutics Inc (ACOR.O)
20 Jan 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|60||President,Chief Executive Officer, Director|
|59||2016||Chief Business Operations, Principal Accounting Officer|
|64||2004||Chief Scientific Officer|
|60||2012||President - International, General Counsel, Corporate Secretary|
|60||2016||Chief Medical Officer|
- BRIEF-Acorda announces 2016 AMPYRA net sales and 2017 financial guidance
- BRIEF-Acorda to discontinue development of Dalfampridine for treatment of post-stroke walking difficulties
- BRIEF-Acorda Therapeutics Q3 non-GAAP loss per share $0.04
- BRIEF-Acorda Therapeutics presents data from clinical and preclinical trials of CVT-301
- BRIEF-Arbitral Tribunal confirms Acorda's redemption right regarding Biotie shares